PBYI Overview

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.

Wall Street analysts forecast PBYI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Puma Biotechnology Inc revenue for the last quarter amounts to 75.45M USD, increased 27.72

Puma Biotechnology Inc. EPS for the last quarter amounts to 0.26 USD, decreased -33.33

Puma Biotechnology Inc (PBYI) has 179 emplpoyees as of March 12 2026.

Today PBYI has the market capitalization of 305.26M USD.